Zacks
JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?
📊
AI Sentiment
Positive
6/10
Johnson & Johnson News
Latest updates and market news for JNJ
20 news
Dec 5 - Dec 11, 2025
Page 1
MT Newswires
HSBC Adjusts Price Target on Johnson & Johnson to $240 From $215, Maintains Buy Rating
📊
AI Sentiment
Positive
7/10
Simply Wall St.
Johnson & Johnson (JNJ): Revisiting Valuation After a Strong Multi‑Month Share Price Rally
📈
AI Sentiment
Highly Positive
8/10
Fortune
Jamie Dimon taps Jeff Bezos, Michael Dell, and Ford CEO Jim Farley to advise JPMorgan’s $1.5 trillion national security initiative
📈
AI Sentiment
Highly Positive
8/10
Motley Fool
1 Major Factor Behind the Healthcare Sector's Recent Surge
📈
AI Sentiment
Highly Positive
8/10
24/7 Wall St.
The 5 Best S&P 500 Dividend Aristocrat Stocks to Buy Before 2026
📊
AI Sentiment
Positive
7/10
GlobeNewswire
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
📈
AI Sentiment
Highly Positive
9/10
TheStreet
Stock Market Today: S&P 500, Nasdaq Open Narrowly Lower As Final Fed Meeting of 2025 Kicks Off
📊
AI Sentiment
Positive
6/10
Business Wire
Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference
âž–
AI Sentiment
Neutral
5/10
24/7 Wall St.
Why 2026 Could Be the Breakout Year for Dividend Growth Investors
📈
AI Sentiment
Highly Positive
8/10
24/7 Wall St.
2 Dividend Stocks That Jim Cramer Wants Every Retiree to Own
📈
AI Sentiment
Highly Positive
8/10
Investing.com
Kenvue and J&J must register in Texas or face business ban, judge rules
📉
AI Sentiment
Negative
3/10
Zacks
Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?
âž–
AI Sentiment
Neutral
4/10
The Wall Street Journal
From Condi Rice to Jeff Bezos: The Heavy Hitters on JPMorgan's New Security Council
📊
AI Sentiment
Positive
7/10
MT Newswires
Eli Lilly, Pfizer Feature in China's Commercial Insurance Innovative Drug Catalog
âž–
AI Sentiment
Neutral
5/10
PR Newswire
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study
📈
AI Sentiment
Highly Positive
8/10
BioPharma Dive
At ASH, Lilly makes case to widen Jaypirca use in leukemia, lymphoma
📈
AI Sentiment
Highly Positive
8/10
Share this news page